China-based Hope Medicine Inc. has announced receiving approval to conduct a global multi-center Phase II clinical study for its monoclonal antibody (mAb) HMI-115, targeting the prolactin receptor (PRL R). The drug is being evaluated as a treatment for endometriosis, a condition that affects many women worldwide. This potential first-in-class (FIC) molecule was previously approved for a Phase II study in the US last year.
Licensing and Development
Hope Medicine secured a licensing deal with German pharmaceutical giant Bayer, the drug’s originator, in April 2019. Under the agreement, Hope Medicine obtained global development and industrialization rights to HMI-115 for multiple indications. This strategic partnership aims to accelerate the development and commercialization of HMI-115 globally.
Additional Pipeline
In addition to HMI-115, Hope Medicine has also licensed a drug candidate targeting MG53 from Peking University. This candidate has demonstrated promising therapeutic effects in treating diabetes and its complications, further expanding Hope Medicine’s pipeline and reinforcing its commitment to addressing unmet medical needs.-Fineline Info & Tech
